Skip to content

ADC binding to soluble BCMA and disease-marker dynamics

Independently authored deterministic equation model of two-volume conjugate disposition, rapid soluble-target binding, target renewal and an exposure-dependent disease marker. Source: Clements et al., DOI 10.1002/psp4.70337. It is a reference-subject projection; no population, clinical prediction, figure-parity or fitting claim.

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma ↗

CPT: Pharmacometrics & Systems Pharmacology

Exploration notes · What are you exploring?

Notes stay on this browser.

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

30 mg every 14 days, fixed reference subject

Deterministic equation projection with zero random effects. Population, residual error and trial-median reproduction are not claimed.

0–28 day

Scenario details

30 mg every 14 days, fixed reference subject

Deterministic equation projection with zero random effects. Population, residual error and trial-median reproduction are not claimed.

Readouts

Total ADC · ng/mL
total adc ng mL
Free ADC · ng/mL
free adc ng mL
Assay free target · ng/mL
assay free target ng mL
Assay bound target · ng/mL
assay bound target ng mL
Disease marker g · g/L
disease marker g L

Study purpose

  • How do the model's key biological readouts change under 30 mg every 14 days, fixed reference subject?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
28 → 168

Time between reported samples.

day
0.25 → 1

2 changes · Variation 1

Biology

Independently authored deterministic equation model of two-volume conjugate disposition, rapid soluble-target binding, target renewal and an exposure-dependent disease marker. Source: Clements et al., DOI 10.1002/psp4.70337. It is a reference-subject projection; no population, clinical prediction, figure-parity or fitting claim.

Independently authored deterministic equation model of two-volume conjugate disposition, rapid soluble-target binding, target renewal and an exposure-dependent disease marker. Source: Clements et al., DOI 10.1002/psp4.70337. It is a reference-subject projection; no population, clinical prediction, figure-parity or fitting claim.

Model details

20 parameters · 6 states · 6 equations · 16 derived outputs

Classification & API access
Therapeutic
Belantamab-informed ADC equation projection
Modality
Antibody–drug conjugate (ADC)
Target
BCMA / TNFRSF17 / CD269
Disease / scope
Multiple myeloma reference-subject mechanism
ParameterDefaultUnitDescription
ADC k daadc_kDa152.1kDaadc kDa
Affinityaffinity_nM1.11nmol/Laffinity nM
Serum albuminalbumin_g_L38g/Lalbumin g L
Baseline marker gbaseline_marker_g_L18g/Lbaseline marker g L
Baseline targetbaseline_target_nM12.141666666666666nmol/Lbaseline target nM
Clearanceclearance_L_day0.7L/dayclearance L day
Complex assay dilutioncomplex_assay_dilution10—complex assay dilution
Exchangeexchange_L_day0.771L/dayexchange L day
Extramedullaryextramedullary0—extramedullary
Femalefemale0—female
Free target assay dilutionfree_target_assay_dilution20—free target assay dilution
Marker capacity gmarker_capacity_g_L150g/Lmarker capacity g L
Marker growthmarker_growth_day0.003191/daymarker growth day
Marker killmarker_kill_L_nmol_day0.00019L/nmol/daymarker kill L nmol day
Precursor releaseprecursor_release_day4.451/dayprecursor release day
Serum volumeserum_volume_L4.81Lserum volume L
Target decaytarget_decay_day0.6711/daytarget decay day
Target k datarget_kDa6kDatarget kDa
Tissue volumetissue_volume_L12.7Ltissue volume L
Weightweight_kg74.65kgweight kg

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics